|
|
Post by tchalaa on Oct 25, 2015 6:24:21 GMT -5
After Sanofi, is Teva our next partner? Mannkind Corp. Technosphere® Technology Pipeline • Leading Target Indications - Pain Management*
- Pulmonary Disease*
- Oncology
- Other
*---Targets Selected for 2015 Teva Acquires Labrys Biologics For Positioning In Pain Market Teva currently has a diverse group of approved treatments and investigational drugs for pain, migraine, and cancer. www.clinicalleader.com/doc/teva-acquires-labrys-biologics-for-positioning-in-pain-market-0001
|
|
|
|
Post by jpg on Oct 25, 2015 12:41:59 GMT -5
Historically Teva has never been the greatest partner. That seems to be slowly changing though. Regarless I would hope we can do better than Teva?
|
|
|
|
Post by kc on Oct 25, 2015 12:54:25 GMT -5
They would make a great Buyer and partner for Sanofi. Sanofi would have e a lot of pressure if the company was purchased by Teva.
If Sanofi didn't want to continue selling Afrezza it would give Teva a great inhalable Insulin product. The only one on the market. They have distribution and know how to market and develop. MannKind is a cheap company to buy today.
Things could get very interesting SHORTLY.
|
|
|
|
Post by robsacher on Oct 25, 2015 15:42:27 GMT -5
Teva would not likely buy MannKind but MannKind could manufacture an inhaled version of the Teva MS drug, Copaxone. Copaxone is the leading drug in the MS sector with sales over 4.3 billion dollars last year. Copaxone is going off patent and an inhaled version would make sense in extending Teva's patent.
Also, Israeli government drug approval is virtually assured to be fast tracked and that could place much pressure on the FDA to also approve quickly. Teva is a big company, the largest company across all sectors in Israel. They just bought an Irish pharmaceutical company for over 40 billion dollars last year.
The pros of this deal would seem to be many. In addition, Teva make many generics. There could be more than one or two additional generics with inhaled suitability that can also be fast tracked through Israeli government approval.
On the looks of this, if the rumors are true, this could be Al Mann's end run around the financial issues currently creating a headwind for MannKind.
Also, there was a baffling message on The Street website yesterday telling their readers that Sanofi was very much behind MannKind and working diligently at getting Afrezza into the market. You should go to their website and read the exact quote. It seems like it could be a signal for shorts to return their shares.
All in all, along with MannKind entering the Tel Aviv stock market (this week, I believe) and the additional millions of shares that will be sold to new MNKD investors there, it would seem that Monday should see the start of a potentially huge week for MannKind.
Last, Al Mann has deep pocket friends in Israel and he supports many hospital programs.
|
|
|
|
Post by biotec on Oct 25, 2015 15:54:58 GMT -5
Teva would not likely buy MannKind but MannKind could manufacture an inhaled version of the Teva MS drug, Copaxone. Copaxone is the leading drug in the MS sector with sales over 4.3 billion dollars last year. Copaxone is going off patent and an inhaled version would make sense in extending Teva's patent. Also, Israeli government drug approval is virtually assured to be fast tracked and that could place much pressure on the FDA to also approve quickly. Teva is a big company, the largest company across all sectors in Israel. They just bought an Irish pharmaceutical company for over 40 billion dollars last year. The pros of this deal would seem to be many. In addition, Teva make many generics. There could be more than one or two additional generics with inhaled suitability that can also be fast tracked through Israeli government approval. On the looks of this, if the rumors are true, this could be Al Mann's end run around the financial issues currently creating a headwind for MannKind. Also, there was a baffling message on The Street website yesterday telling their readers that Sanofi was very much behind MannKind and working diligently at getting Afrezza into the market. You should go to their website and read the exact quote. It seems like it could be a signal for shorts to return their shares. All in all, along with MannKind entering the Tel Aviv stock market (this week, I believe) and the additional millions of shares that will be sold to new MNKD investors there, it would seem that Monday should see the start of a potentially huge week for MannKind. Last, Al Mann has deep pocket friends in Israel and he supports many hospital programs. Also Sanofi 3Q call on Thursday. Will be fun to watch what MNKD stock does this week. |
|
|
|
Post by goyocafe on Oct 25, 2015 16:09:52 GMT -5
Teva would not likely buy MannKind but MannKind could manufacture an inhaled version of the Teva MS drug, Copaxone. Copaxone is the leading drug in the MS sector with sales over 4.3 billion dollars last year. Copaxone is going off patent and an inhaled version would make sense in extending Teva's patent. Also, Israeli government drug approval is virtually assured to be fast tracked and that could place much pressure on the FDA to also approve quickly. Teva is a big company, the largest company across all sectors in Israel. They just bought an Irish pharmaceutical company for over 40 billion dollars last year. The pros of this deal would seem to be many. In addition, Teva make many generics. There could be more than one or two additional generics with inhaled suitability that can also be fast tracked through Israeli government approval. On the looks of this, if the rumors are true, this could be Al Mann's end run around the financial issues currently creating a headwind for MannKind. Also, there was a baffling message on The Street website yesterday telling their readers that Sanofi was very much behind MannKind and working diligently at getting Afrezza into the market. You should go to their website and read the exact quote. It seems like it could be a signal for shorts to return their shares. All in all, along with MannKind entering the Tel Aviv stock market (this week, I believe) and the additional millions of shares that will be sold to new MNKD investors there, it would seem that Monday should see the start of a potentially huge week for MannKind. Last, Al Mann has deep pocket friends in Israel and he supports many hospital programs. Also Sanofi 3Q call on Thursday. Will be fun to watch what MNKD stock does this week. And short lending interest rates. What was the peak earlier this summer? Would love to see another 2 pt jump. |
|
|
|
Post by gamblerjag on Oct 25, 2015 16:24:18 GMT -5
This just proves my point of crazy speculation. Rarely, extremely rare do the public know what's coming.. No one saw this Televiv exchange coming. So many YMB (not here so much until lately) posters talked all about this crazy b/o scenarios with SNY, MDT, and several other scenarios have not came to fruition. Just like Weight Watcher and Oprah.. no one saw that coming....... So why people speculate, lets remember 95% it doesn't pan out.
|
|
|
|
Post by rrtzmd on Oct 25, 2015 19:03:00 GMT -5
After Sanofi, is Teva our next partner? Mannkind Corp. Technosphere® Technology Pipeline • Leading Target Indications - Pain Management*
- Pulmonary Disease*
- Oncology
- Other
*---Targets Selected for 2015 Teva Acquires Labrys Biologics For Positioning In Pain Market Teva currently has a diverse group of approved treatments and investigational drugs for pain, migraine, and cancer. www.clinicalleader.com/doc/teva-acquires-labrys-biologics-for-positioning-in-pain-market-0001 Why would listing in Tel Aviv have anything to do with Teva? Teva has made deals with and/or bought outright dozens of companies over the years -- have any of them been preceded by listing in Israel before the deal was made? Teva just bought Rimsa for 2 billion, I'm pretty sure Rimsa didn't list in Tel Aviv beforehand. |
|
